Growth hormone deficiency natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
*If left untreated, | *If left untreated, may progress to develop | ||
*Common complications of | *Common complications of growth hormone deficiency include | ||
*Prognosis is generally | *Prognosis is generally good with treatment. | ||
==Natural History, Complications, and Prognosis== | ==Natural History, Complications, and Prognosis== | ||
===Natural History=== | ===Natural History=== | ||
*The symptoms of growth hormone deficiency usually develop in the first days of life and start with symptoms such as perinatal asphyxia, neonatal hypoglycemia, reduced birth length, and prolonged jaundice especially if associated with ACTH deficiency. If left untreated, patients with growth hormone deficiency may progress to develop delayed postnatal growth | *The symptoms of growth hormone deficiency usually develop in the first days of life and start with symptoms such as perinatal [[asphyxia]], neonatal [[hypoglycemia]], reduced birth length, and prolonged [[jaundice]] especially if associated with [[Adrenocorticotropic hormone|ACTH]] deficiency. If left untreated, patients with growth hormone deficiency may progress to develop delayed postnatal growth, delayed bone age, delayed puberty, infantile fat distribution, and infantile voice. | ||
===Complications=== | ===Complications=== | ||
*Patients less healthy and less energetic than normal people of the same age. | *Patients less healthy and less energetic than normal people of the same age. | ||
* The degree of osteopenia appears to correlate directly with the degree of | *Fractures of the [[lumbar spine]] are somewhat lower in patients with adult-onset [[Growth hormone|GH]] deficiency. | ||
* The degree of [[osteopenia]] appears to correlate directly with the degree of [[Growth hormone|GH]] deficiency. | |||
* '''Cardiovascular complications''' | * '''Cardiovascular complications''' | ||
** Dyslipidemia<sup>[[Growth hormone deficiency history and symptoms#cite note-pmid10566630-7|[7]]]</sup> | ** [[Dyslipidemia]]<sup>[[Growth hormone deficiency history and symptoms#cite note-pmid10566630-7|[7]]]</sup> | ||
** Increased inflammatory markers<sup>[[Growth hormone deficiency history and symptoms#cite note-pmid11739438-8|[8]]]</sup> | ** Increased inflammatory markers (ESR)<sup>[[Growth hormone deficiency history and symptoms#cite note-pmid11739438-8|[8]]]</sup> | ||
** Increase in biochemical markers of endothelial dysfunction<sup>[[Growth hormone deficiency history and symptoms#cite note-pmid11549653-9|[9]]]</sup> | ** Increase in biochemical markers of [[Endothelium|endothelial]] dysfunction<sup>[[Growth hormone deficiency history and symptoms#cite note-pmid11549653-9|[9]]]</sup> | ||
** High coronary calcium scores (a marker of subclinical atherosclerosis)<sup>[[Growth hormone deficiency history and symptoms#cite note-pmid20511726-10|[10]]]</sup> | ** High coronary calcium scores (a marker of [[Atherosclerosis|subclinical atherosclerosis]])<sup>[[Growth hormone deficiency history and symptoms#cite note-pmid20511726-10|[10]]]</sup> | ||
* Mortality | * Mortality | ||
Patients with | Patients with growth hormone deficiency have a mortality rate twice that of normal subjects, a difference due to an increased number of cardiovascular events.<ref name="pmid16597813">{{cite journal| author=Prabhakar VK, Shalet SM| title=Aetiology, diagnosis, and management of hypopituitarism in adult life. | journal=Postgrad Med J | year= 2006 | volume= 82 | issue= 966 | pages= 259-66 | pmid=16597813 | doi=10.1136/pgmj.2005.039768 | pmc=2585697 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16597813 }}</ref> | ||
==Prognosis== | ==Prognosis== | ||
*Since recombinant DNA–derived growth hormone became available, most children with growth hormone deficiency reach normal adult stature. | *Since [[Recombinant DNA|recombinant]] DNA–derived growth hormone became available, most children with growth hormone deficiency reach normal adult stature. | ||
*Initiate growth hormone therapy as early as possible and continue therapy through adolescence to ensure the best chance of achieving height potential. | *Initiate growth hormone therapy as early as possible and continue therapy through adolescence to ensure the best chance of achieving height potential. | ||
Line 32: | Line 33: | ||
*In the first year of treatment, the rate of growth may increase from half as fast as other children are growing to twice as fast. | *In the first year of treatment, the rate of growth may increase from half as fast as other children are growing to twice as fast. | ||
* Growth typically slows in subsequent years, but usually remains above normal so that over several years a child who had fallen far behind in his height may grow into the normal height range. Excess adipose tissue may be reduced. | * Growth typically slows in subsequent years, but usually remains above normal so that over several years a child who had fallen far behind in his height may grow into the normal height range. Excess [[adipose tissue]] may be reduced. | ||
=== Adulthood === | === Adulthood === | ||
GH treatment can confer a number of measurable benefits to severely GH-deficient adults, such as enhanced energy and strength, and improved bone density. Muscle mass may increase at the expense of adipose tissue. Although adults | * GH treatment can confer a number of measurable benefits to severely GH-deficient adults, such as enhanced energy and strength, and improved [[bone density]]. Muscle mass may increase at the expense of [[adipose tissue]]. | ||
* Although adults with [[hypopituitarism]] have been shown to have a reduced life expectancy, and a cardiovascular [[mortality rate]] more than double controls<ref name="pmid16597813" />, treatment has not been shown to improve [[Mortality rate|mortality]] even after improved [[Blood lipids|blood lipid]] levels. | |||
* Although measurements of [[bone density]] improve with treatment, rates of fractures have not been shown to improve. | |||
==References== | ==References== |
Revision as of 23:10, 16 August 2017
Growth hormone deficiency Microchapters |
Differentiating Growth hormone deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Growth hormone deficiency natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Growth hormone deficiency natural history, complications and prognosis |
FDA on Growth hormone deficiency natural history, complications and prognosis |
CDC on Growth hormone deficiency natural history, complications and prognosis |
Growth hormone deficiency natural history, complications and prognosis in the news |
Blogs on Growth hormone deficiency natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
- If left untreated, may progress to develop
- Common complications of growth hormone deficiency include
- Prognosis is generally good with treatment.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of growth hormone deficiency usually develop in the first days of life and start with symptoms such as perinatal asphyxia, neonatal hypoglycemia, reduced birth length, and prolonged jaundice especially if associated with ACTH deficiency. If left untreated, patients with growth hormone deficiency may progress to develop delayed postnatal growth, delayed bone age, delayed puberty, infantile fat distribution, and infantile voice.
Complications
- Patients less healthy and less energetic than normal people of the same age.
- Fractures of the lumbar spine are somewhat lower in patients with adult-onset GH deficiency.
- The degree of osteopenia appears to correlate directly with the degree of GH deficiency.
- Cardiovascular complications
- Dyslipidemia[7]
- Increased inflammatory markers (ESR)[8]
- Increase in biochemical markers of endothelial dysfunction[9]
- High coronary calcium scores (a marker of subclinical atherosclerosis)[10]
- Mortality
Patients with growth hormone deficiency have a mortality rate twice that of normal subjects, a difference due to an increased number of cardiovascular events.[1]
Prognosis
- Since recombinant DNA–derived growth hormone became available, most children with growth hormone deficiency reach normal adult stature.
- Initiate growth hormone therapy as early as possible and continue therapy through adolescence to ensure the best chance of achieving height potential.
Childhood
- In the first year of treatment, the rate of growth may increase from half as fast as other children are growing to twice as fast.
- Growth typically slows in subsequent years, but usually remains above normal so that over several years a child who had fallen far behind in his height may grow into the normal height range. Excess adipose tissue may be reduced.
Adulthood
- GH treatment can confer a number of measurable benefits to severely GH-deficient adults, such as enhanced energy and strength, and improved bone density. Muscle mass may increase at the expense of adipose tissue.
- Although adults with hypopituitarism have been shown to have a reduced life expectancy, and a cardiovascular mortality rate more than double controls[1], treatment has not been shown to improve mortality even after improved blood lipid levels.
- Although measurements of bone density improve with treatment, rates of fractures have not been shown to improve.
References
- ↑ 1.0 1.1 Prabhakar VK, Shalet SM (2006). "Aetiology, diagnosis, and management of hypopituitarism in adult life". Postgrad Med J. 82 (966): 259–66. doi:10.1136/pgmj.2005.039768. PMC 2585697. PMID 16597813.